BACKGROUND: Propofol-evoked injection site pain is not observed with fospropofol. We hypothesized that unlike propofol, fospropofol does not activate the irritant receptor, transient receptor potential 1 (TRPA1). METHODS: We tested the hypothesis using electrophysiology and behavioral studies. RESULTS: Our data demonstrate that propofol (100 M) evokes an inward current only in TRPA1-expressing neurons. However, fospropofol (100 M and 1 mM) is unable to evoke depolarizing currents in either TRPA1-positive or TRPA1-negative neurons. Both propofol and fospropofol produced general anesthesia. CONCLUSIONS: The lack of algogenic activity in fospropofol is most likely the result of its inability to activate TRPA1 on nociceptors. (Anesth Analg 2012;115:837-40) 
T he IV general anesthetic propofol has been widely used for induction and maintenance of general anesthesia for decades. One of the common side effects observed with the use of propofol as an induction drug is injection site pain. 1 Irritation evoked by propofol can result in undesirable patient movement at induction. Moreover, propofol injection/infiltration can lead to development of thrombophlebitis/tissue inflammation. 2 Interestingly, fospropofol, a recently approved prodrug of propofol, does not cause injection site pain. 3 Multiple mechanisms have been proposed to explain the algogenic properties of propofol, and they include the solvent used, emulsion formulation, etc. 4 A more recent study demonstrated propofol-induced activation of an ion channel known as transient receptor potential A1 (TRPA1), which is expressed by nociceptors, as a more likely explanation for propofol-evoked pain. 5 TRPA1 is a cation selective ion channel that belongs to a larger family of TRP channels, many of which are expressed by nociceptors and serve as sensors for various harmful stimuli such as heat, chemicals, and acid. 6 TRPA1 is activated by environmental irritants such as cigarette smoke, certain pungent chemicals (e.g., mustard oil [MO] , wasabi, and desflurane), and possibly by noxious cold. 7, 8 In the current study, we hypothesized that the lack of injection site pain upon fospropofol administration is due to its inability to activate TRPA1. We conducted single-cell electrophysiological studies on dissociated rat trigeminal ganglia (TG) neurons. Behavioral studies were also performed to assess the anesthetic efficacy of propofol and fospropofol.
METHODS Animals
Adult male Sprague-Dawley rats (200 to 225 g; Harlan, Indianapolis, IN) were maintained in a climate-controlled room on a 12-hour light/dark cycle (lights on 7 am, lights off 7 pm) with food and water ad libitum. All procedures were performed in accordance with the policies and recommendations of the International Association for the Study of Pain and the National Institutes of Health guidelines for the handling and use of laboratory animals, and were approved by the Institutional Animal Care and Use Committee of the University of Arizona.
Drugs
Allyl isothiocyanate (AITC) was purchased from Sigma (St. Louis, MO). Propofol and fospropofol disodium were obtained in clinical formulation from the University of Arizona pharmacy. For patch-clamp experiments, MO and propofol were dissolved in dimethylsulfoxide to 10 mM as a stock solution and diluted to the 100-M concentration with external bath solution. Final dimethylsulfoxide concentration never exceeded 0.1% for patch-clamp experiments. Fospropofol was diluted directly in an external bath to final concentrations of 100 M and 1 mM. For the in vivo experiments, effective doses of propofol (10 mg/kg) and fospropofol (45 mg/kg) were administered IV.
Cell Culture
TG were removed, enzymatically treated, and mechanically dissociated as previously described. Briefly, rats were anesthetized with isoflurane (Phoenix Pharmaceuticals, Burlingame, CA) and killed by decapitation. The TG were removed and placed in ice-cold Hanks balanced-salt solution (divalent free). Ganglia were cut into small pieces and incubated for 25 minutes in 20 U/mL Papain (Worthington, Lakewood, NJ) followed by 25 minutes in 3 mg/mL Collagenase type II (Worthington). Ganglia were then triturated through fire-polished Pasteur pipettes and plated on poly-d-lysine-coated (Becton Dickinson, Franklin Lakes, NJ) and laminin-coated (Sigma) 35-mm plates. After several hours at room temperature to allow adhesion, cells were cultured in a room-temperature, humidified chamber in Liebovitz L-15 medium supplemented with 10% fetal bovine serum, 10 mM glucose, 10 mM HEPES, 50 U/mL penicillin/streptomycin, and 50 ng/mL nerve growth factor. Cells were used within 24 hours post plating.
Electrophysiology
Whole-cell patch-clamp experiments were performed on isolated rat TG using a MultiClamp 700B (Axon Instruments) patch-clamp amplifier and pClamp 10 acquisition software (Axon Instruments, Union City, CA). Recordings were sampled at 5 kHz and filtered at 1 kHz (Digidata 1322A, Axon Instruments). Pipettes (OD: 1.5 mm, ID: 0.86 mm; Sutter Instrument, Novato, CA) were pulled using a P-97 puller (Sutter Instrument) and heat polished to 2.5 to 4 M⍀ resistance using a microforge (MF-83, Narishige, Tokyo, Japan). Series resistance was typically Ͻ7 M⍀ and was compensated 60%. All recordings were performed at room temperature. A Nikon TE2000-S Microscope was used to identify TG cells. Data were analyzed using Clampfit 10 (Molecular Devices, Sunnyvale, CA) and Origin 8 (OriginLab, Northampton, MA). Pipette solution contained (in mM) 140 KCl, 11 EGTA, 2 MgCl 2 , 10 NaCl, 10 HEPES, 2 MgATP, and 0.3 Na 2 GTP, 1CaCl 2 pH 7.3 (adjusted with N-methyl glucamine), and was ϳ320 mOsm. External solution contained (in mM) 135 NaCl, 2 CaCl 2 , 1 MgCl 2 , 5 KCl, 10 glucose, 10 HEPES, pH 7.4 (adjusted with N-methyl glucamine), and was ϳ320 mOsm. Solutions were rapidly changed during recordings (exchange time was ϳ20 ms) using gravity-fed flow pipes positioned near the cell and controlled by computer-driven solenoid valves. Four different test solutions were applied for 2 minutes to each cell. The order of the solutions was varied from cell to cell with no effect on the outcome of the recordings. All electrophysiological data are presented as cell counts or as a percentage of TRPA1-expressing neurons.
In Vivo Anesthesia
Intravenous tail vein injections were performed by placing the animal into a rat restrainer (VWR International, LLC, Radnor, PA) and holding the tail in warm water for 5 seconds to dilate the tail vein. A 30-gauge needle was inserted into the tail vein, and propofol or fospropofol was injected. Bolus injections of the anesthetics were performed over a 10-second period and were noted as positive by the presence of blood in the tip of the syringe before injection and the absence of an out-pocketing of the tail-skin at the site of injection. Immediately after injection, animals were removed from the restrainer and the time to anesthesia was recorded (as defined by the loss of righting reflex), 9 and the time to first movement was observed to calculate duration of anesthesia. Anesthesia data are presented as means Ϯ SEM.
RESULTS
Patch-clamp electrophysiology was performed on cultured TG neurons taken from rats. TRPA1-expressing sensory neurons were identified using application of the known specific TRPA1-agoinst MO (100 M). Among 25 cells recorded, 52% expressed the TRPA1 receptor as evidenced by MO-evoked currents (Fig. 1A) . All 13 neurons that exhibited MO-evoked current also exhibited TRPA1-like current in response to propofol (100 M) ( Fig. 1A) . Propofol concentrations were chosen on the basis of the dose responses performed in previous studies. 5, 10, 11 We used the clinically available formulations of both propofol and fospropofol to keep our observations consistent with human studies. Although it has been reported that the aqueous portion of propofol may vary depending upon the formulation, the clinical efficacy and pharmacokinetics are unchanged. 12 The propofol current was similar to that previously reported by Matta et al. and therefore would unlikely be the result of TRPV1 or TRPM8 channel activation. 5 Additionally, the carrier solvent for propofol is not the cause of TRPA1 activation because it has been shown that application of the carrier produces no increase in intracellular calcium when applied to cultured dorsal root ganglion neurons, nor does it produce pain upon injection in human subjects. 10 Cells expressing TRPA1-like currents were not activated by a comparable concentration of fospropofol (100 M) (Fig. 1A) . Clinically, fospropofol requires a higher concentration than does propofol for effective anesthesia. 13 To exclude the possibility that TRPA1 activation by fospropofol requires a higher effective concentration, a 1-mM fospropofol solution was applied to TRPA1-positive neurons, and no apparent current was observed (Fig. 1A) . The 12 neurons identified as TRPA1-negative cells (defined by the absence of MOevoked current) did not express current after either propofol or fospropofol solution application (Fig. 1B) . These data indicate that fospropofol is not an agonist for the TRPA1 receptor on sensory neurons.
To demonstrate that the clinical formulations used in our in vitro patch-clamp studies were biologically active, we performed an in vivo study to characterize general anesthesia induced by both drugs. Propofol (10 mg/kg) induced an immediate state of anesthesia in Ͻ10 seconds after a single bolus IV injection with duration of anesthesia lasting 7.44 Ϯ 0.32 minutes (n ϭ 6). Fospropofol (45 mg/kg) induced full anesthesia more gradually in 2.57 Ϯ 0.16 minutes with duration of anesthesia lasting 16.38 Ϯ 1.19 minutes (n ϭ 6). These data are consistent with previous clinical reports concerning both dosing and the pharmacokinetics of the 2 drugs. 13 Moreover, some rats injected with propofol demonstrated pain-like behavior (vocalization, flicking of the tail, withdrawal responses), whereas those with fospropofol did not. However, these were qualitative observations and were not quantifiable, given the very short duration of the behavior. We performed further studies to evaluate whether propofol evokes nocifensive behavior upon application to the nasal mucosa or the cornea and were unable observe any nocifensive responses to either drug in any assay. The data indicate that the clinical formulation of fospropofol is biologically active in rats, and the lack of efficacy at the TRPA1 receptor is unrelated to species difference.
DISCUSSION
In the present study we demonstrated that unlike propofol, fospropofol does not activate TRPA1, providing a mechanistic explanation for its lack of algogenic properties. However, both drugs were effective in inducing general anesthesia, demonstrating biological activity. Moreover, in vivo studies confirmed pharmacokinetic properties of fospropofol observed in humans, i.e., higher dose requirement and slower onset and offset.
Injection site pain is a very undesirable side effect of propofol. Although not very common, thrombophlebitis or tissue inflammation upon infiltration is a more serious consequence of irritation evoked by propofol. 14, 15 Various measures are taken to reduce this side effect, and they include lidocaine pre-or coinjection, slower rate of injection, use of large bore IV, etc. 4 However, most of these measures are at best partly effective and may not be possible in all patients (e.g., lidocaine allergy, difficult IV access). Multiple mechanisms have been proposed to explain the irritation caused by propofol, and they include the emulsion formulation, vehicle used, etc. However, an elegant study by Matta et al. demonstrated a receptorspecific mechanism via activation of TRPA1 as a more likely explanation, given that the vehicle itself did not evoke any pain-like behavior in animals and that propofolevoked pain was virtually absent in TRPA1 knockout mice. 5 TRPA1-expressing nerve terminals surrounding the vessels are the likely target of propofol. Our study demonstrates that fospropofol lacks the TRPA1 agonist activity characteristic of propofol and very likely explains the lack of algogenic properties of fospropofol in humans.
More recent studies have demonstrated that propofol also activates other ion channels expressed on nociceptors such as TRPV1. 10 However, propofol-evoked nociceptor excitation and pain-like behavior in animals was absent in TRPA1 knockout mice and blocked by a TRPA1 antagonist, suggesting that the contribution of other ion channels in propofol-evoked pain is minimal. Moreover, it should be noted that propofol did not evoke current in TRPA1negative neurons in the current study, and fospropofol was unable to evoke any current in any of the TG neurons (both TRPA1 expressing and nonexpressing) that were tested. Therefore, it is unlikely that fospropofol activates any other ion channels in sensory neurons.
Although fospropofol does not evoke pain at the injection site, the prodrug nature mandates hepatic metabolism before bioactivity is observed and results in slower onset and offset, not a desirable property in an ideal induction/maintenance drug. There are various possibilities that may account for the difference in the algogenic properties of propofol and fospropofol: (1) Stereospecificity: although the binding site of propofol on TRPA1 is not known, our study demonstrates that addition of the phos group in fospropofol may hinder that interaction. (2) Solubility: if the propofol binding site on TRPA1 is intracellular, it is possible that lipophilic propofol reaches the intracellular compartment more readily than does the hydrophilic fospropofol. (3) A distant possibility is that fospropofol has antagonist or cross-desensitizing activity on TRPA1 via action of some other receptor expressed by sensory neurons. A moiety in propofol structure that is responsible for TRPA1 activity but not essential for ␥-aminobutyric acid A binding could be identified. This information is of potential use in molecular modeling studies in which the structural difference between propofol and fospropofol could serve as a template to design propofol-like molecules that are not prodrugs but nonalgogenic as well.
Finally, although not a major focus of the study, we observed that the pharmacokinetic profile of fospropofol in rats is similar to that seen in humans. To the best of our knowledge, this is the first published report of characterization of fospropofol in a rodent model. Future studies could use this model to study the interaction of various drugs that can potentially affect in vivo efficacy of fospropofol (e.g., hepatic inducers/inhibitors).
In conclusion, we demonstrated that the lack of algogenic properties of fospropofol is likely due to its inability to activate TRPA1 or any other ion channels on sensory neurons. Moreover, the pharmacokinetic profile of fospropofol was established in a rodent model that can be used for future studies.
